Article
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
The pharmacogenomics journal - 1 Apr 2021
Vivaldi Caterina, Crucitta Stefania, Catanese Silvia, Cucchiara Federico, Arrigoni Elena, Pecora Irene, Rofi Eleonora, Fornaro Lorenzo, Salani Francesca, Massa Valentina, Vasile Enrico, Morganti Riccardo, Danesi Romano, Del Re Marzia
Abstract excerpt
Modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine + nab-paclitaxel (GemNab) regimens represent a standard treatment in advanced pancreatic cancer (aPC). DPYD and UGT1A1 variants are relevant predictors of fluoropyrimidine and irinotecan-associated adverse events (AEs). Furthermore, data about the associations between polymorphisms in ABCB and CDA genes and GemNab-related toxicities are still controversial. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.